Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01387854 · ClinicalTrials.gov registry record
Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 59
- Enrollment target
NCT01387854 is a clinical trial that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 59 participants.
The verdict
NCT01387854 has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 59 participants
- Enrollment target
Study Summary
There is limited information on the long-term effects of treating patients with MPS VI with Naglazyme® and limited data on the natural history of treated and untreated MPS VI patients. The Re-survey Study ASB-00-03 will assist in understanding the effects of long-term Naglazyme treatment and the natural history of the MPS VI patient population.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01387854
The ClinicalTrials.gov registry entry for NCT01387854 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01387854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01387854 about?
NCT01387854 is a clinical study titled "Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02". There is limited information on the long-term effects of treating patients with MPS VI with Naglazyme® and limited data on the natural history of treated and untreated MPS VI patients. The Re-survey Study ASB-00-03 will assist in understanding the effects of long-term Naglazyme treatment and the nat...
What is the current status of trial NCT01387854?
This trial is currently completed. The enrollment target is 59 participants. The study started on 2011-06. Estimated completion is 2013-02.
Who is sponsoring clinical trial NCT01387854?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.